Global Lutetium-177 Market Size is valued at USD 2.11 Bn in 2024 and is predicted to reach USD 7.41 Bn by the year 2034 at a 11.6% CAGR during the forecast period for 2025-2034.
Lutetium-177 (Lu-177) is a radioactive isotope employed in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer. Being a medium-energy beta emitter with a half-life of 6.7 days, it targets regional radiation with minimal injury to normal tissues. Lu-177 is manufactured in two types: Non-Carrier-Added (NCA) Lu-177, which has high purity and high specific activity, a requirement for precision medicine, and Carrier-Added (CA) Lu-177, a cheaper but lower specific activity type with proven production processes.
It is used in peptide receptor radionuclide therapy (PRRT) and PSMA-directed therapies, as well as in radiopharmaceutical research and nuclear medicine. One of the main drivers of the Lu-177 market is the growing need for targeted radiotherapy solutions in the face of escalating global cancer incidence. With healthcare providers looking for effective treatments with fewer side effects, the precision and effectiveness of Lu-177 make it a go-to option. Moreover, advancements in nuclear medicine and supportive regulatory frameworks also propel its uptake, ensuring sustained market growth and innovation in cancer therapy.
Some of the Key Players in Lutetium-177 Market:
The lutetium-177 market is segmented by application, type, product type, scale of operation, end user, production, technology. By application, the market is segmented into oncology, non-oncology. Oncology is sub segmented mCRPC, NETs, RCC, and other cancers. Non-oncology is sub segmented into arthritis, other. By type market is segmented into carrier-added lutetium-177, no-carrier-added lutetium-177. By Product type the market is segmented into approved drugs, pipeline drugs, investigational drugs. Approved Drugs is sub segmented into, Pluvicto (Pro), Lutathera (Pro). By scale of operation the market is segmented into preclinical, clinical, commercial. By end-user the market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, research institutions/CROs. By production the market is segmented into reactor-based, cyclotron-based. By technology, the market is segmented into targeting ligands, production innovations, combination therapies.
The market for lutetium-177 (Lu-177) is largely driven by targeting ligands, which allow beta radiation to be precisely delivered to cancer cells while avoiding damage to healthy tissue. By attaching to tumor-specific receptors, these ligands—peptides, antibodies, or small molecules—increase treatment effectiveness and reduce adverse effects. Additionally, their application facilitates a theranostic strategy by enabling imaging to find qualified patients prior to treatment. New ligands for other tumors have been developed as a result of the successful treatment of prostate and neuroendocrine cancers, increasing applications and speeding up market expansion.
The No-Carrier-Added (NCA) Lutetium-177 segment is experiencing significant growth in the Lu-177 market due to its high purity and superior specific activity. Produced via the indirect method by irradiating ytterbium-176 (Yb-176), NCA Lu-177 lacks Lu-177m, resulting in a purer product with enhanced therapeutic concentrations and reduced radioactive waste. Its higher efficacy and minimal side effects make it the preferred choice for targeted therapies such as peptide receptor radionuclide therapy (PRRT) and PSMA-targeted treatments, driving its increasing adoption in precision cancer treatment.
North America dominates the Lutetium-177 (Lu-177) market due to its sophisticated healthcare infrastructure, high incidence of cancer, and robust research and development efforts. The region's advanced medical facilities enable the extensive use of Lu-177 therapies for the treatment of neuroendocrine tumors and prostate cancer. North America is also home to many pharmaceutical and biotech firms involved in cancer research, which encourages innovation and drives the uptake of Lu-177 in targeted radionuclide therapies.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 2.11 Bn |
| Revenue forecast in 2034 | USD 7.41 Bn |
| Growth Rate CAGR | CAGR of 11.6% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2034 |
| Historic Year | 2021 to 2023 |
| Forecast Year | 2024-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Application, Type, Product Type, Scale of Operation, End User, Production, Technology and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Novartis AG, Curium, Telix Pharmaceuticals, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), Radiopharm Theranostics, Advanced Accelerator Applications (AAA), Evergreen Theragnostics, Nusano Inc., Nordic Nanovector |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lutetium-177 Market Snapshot
Chapter 4. Global Lutetium-177 Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Lutetium-177 Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Radiopharma Industry Trends
Chapter 5. Lutetium-177 Market Segmentation 1: By Application, Estimates & Trend Analysis
5.1. Market Share by Application, 2023 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Application:
5.2.1. Oncology
5.2.1.1. mCRPC
5.2.1.2. NETs
5.2.1.3. RCC
5.2.1.4. Other Cancers
5.2.2. Non-Oncology
5.2.2.1. Arthritis
5.2.2.2. Other
Chapter 6. Lutetium-177 Market Segmentation 2: By Type, Estimates & Trend Analysis
6.1. Market Share by Type, 2023 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Type:
6.2.1. Carrier-Added Lutetium-177
6.2.2. No-Carrier-Added Lutetium-177
Chapter 7. Lutetium-177 Market Segmentation 3: By Product Type, Estimates & Trend Analysis
7.1. Market Share by Product Type 2023 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Product Type:
7.2.1. Approved Drugs
7.2.1.1. Pluvicto (Pro)
7.2.1.2. Lutathera (Pro)
7.2.2. Pipeline Drugs
7.2.3. Investigational Drug
Chapter 8. Lutetium-177 Market Segmentation 4: By Scale of Operation, Estimates & Trend Analysis
8.1. Market Share by Scale of Operation, 2023 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Scale of Operation:
8.2.1. Preclinical
8.2.2. Clinical
8.2.3. Commercial
Chapter 9. Lutetium-177 Market Segmentation 5: By End-user, Estimates & Trend Analysis
9.1. Market Share by End-user, 2023 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following End-user:
9.2.1. Hospitals & Clinics
9.2.2. Pharmaceutical & Biotechnology Companies
9.2.3. Research Institutions/CROs
Chapter 10. Lutetium-177 Market Segmentation 6: By Production, Estimates & Trend Analysis
10.1. Market Share by Production, 2023 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Production:
10.2.1. Reactor-Based
10.2.2. Cyclotron-Based
Chapter 11. Lutetium-177 Market Segmentation 7: By Technology, Estimates & Trend Analysis
11.1. Market Share by Technology, 2023 & 2034
11.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Technology:
11.2.1. Targeting Ligands
11.2.2. Production Innovations
11.2.3. Combination Therapies
Chapter 12. Lutetium-177 Market Segmentation 8: Regional Estimates & Trend Analysis
12.1. Global Lutetium-177 Market, Regional Snapshot 2023 & 2034
12.2. North America
12.2.1. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
12.2.1.1. US
12.2.1.2. Canada
12.2.2. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.2.3. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
12.2.4. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Product Type 2021-2034
12.2.5. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
12.2.6. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
12.2.7. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Production, 2021-2034
12.2.8. North America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.3. Europe
12.3.1. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
12.3.1.1. Denmark
12.3.1.2. Finland
12.3.1.3. Austria
12.3.1.4. France
12.3.1.5. Germany
12.3.1.6. Israel
12.3.1.7. Italy
12.3.1.8. Netherlands
12.3.1.9. Norway
12.3.1.10. Poland
12.3.2. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.3.3. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
12.3.4. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Product Type 2021-2034
12.3.5. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
12.3.6. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
12.3.7. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Production, 2021-2034
12.3.8. Europe Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts Technology, 2021-2034
12.4. Asia Pacific
12.4.1. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
12.4.1.1. Australia
12.4.1.2. China
12.4.1.3. India
12.4.1.4. Indonesia
12.4.1.5. Japan
12.4.1.6. Malaysia
12.4.1.7. Philippines
12.4.1.8. Singapore
12.4.1.9. South Korea
12.4.1.10. Taiwan
12.4.1.11. Thailand
12.4.1.12. Rest of APAC
12.4.2. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.4.3. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
12.4.4. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts By Product Type 2021-2034
12.4.5. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
12.4.6. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
12.4.7. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Production, 2021-2034
12.4.8. Asia Pacific Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.5. Latin America
12.5.1. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
12.5.1.1. Argentina
12.5.1.2. Brazil
12.5.1.3. Mexico
12.5.1.4. Rest of LATAM
12.5.2. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.5.3. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
12.5.4. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Product Type 2021-2034
12.5.5. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
12.5.6. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
12.5.7. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Production, 2021-2034
12.5.8. Latin America Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
12.6. Middle East & Africa
12.6.1. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
12.6.1.1. Egypt
12.6.1.2. Israel
12.6.1.3. Nigeria
12.6.1.4. Saudi Arabia
12.6.1.5. Qatar
12.6.1.6. United Arab Emirates
12.6.1.7. Rest of MEA
12.6.2. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
12.6.3. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
12.6.4. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Product Type 2021-2034
12.6.5. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
12.6.6. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
12.6.7. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Production, 2021-2034
12.6.8. Middle East & Africa Lutetium-177 Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Novartis AG
13.2.1.1. Business Overview
13.2.1.2. Key Product/Service
13.2.1.3. Financial Performance
13.2.1.4. Modeance
13.2.1.5. Geographical Presence
13.2.1.6. Recent Developments with Business Strategy
13.2.2. Curium
13.2.3. Telix Pharmaceuticals
13.2.4. ITM Isotope Technologies
13.2.5. Eli Lilly (via POINT Biopharma)
13.2.6. Radiopharm Theranostics
13.2.7. Advanced Accelerator Applications (AAA)
13.2.8. Evergreen Theragnostics
13.2.9. Nusano Inc.
13.2.10. Nordic Nanovector
Segmentation of Lutetium-177 Market -
Lutetium-177 Market by Application-
Lutetium-177 Market by Type-
Lutetium-177 Market by Product Type-
Lutetium-177 Market by Scale of Operation-
Lutetium-177 Market by End-user-
Lutetium-177 Market by Production-
Lutetium-177 Market by Technology-
Lutetium-177 Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-